Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01787617 · ClinicalTrials.gov registry record · NA

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men

A NA study of Type 2 Diabetes and Insulin Resistance, sponsored by Pennington Biomedical Research Center.

Completed
Registry status
NA
Development phase
113
Enrollment target
1
Study location

NCT01787617 is a NA study of Type 2 Diabetes and Insulin Resistance that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 113 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01787617, a NA study of Type 2 Diabetes and Insulin Resistance, has completed, sponsored by Pennington Biomedical Research Center.

COMPLETED
Registry status
NA
Development phase
113 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the effect of an exercise training intervention on the ability of African American males to use insulin properly. Insulin is a hormone that helps the body use glucose.

Interventions

  • BEHAVIORAL Control Group
  • BEHAVIORAL Aerobic Plus Resistance Training Group

Study Locations (1)

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2012-12
Est. Completion 2018-03-31
Phase NA

What the Registry Record Tells You About NCT01787617

The ClinicalTrials.gov registry entry for NCT01787617 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (90% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.

NCT01787617 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT01787617 about?

NCT01787617 is a clinical study titled "Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men". The purpose of this study is to investigate the effect of an exercise training intervention on the ability of African American males to use insulin properly. Insulin is a hormone that helps the body use glucose.

What is the current status of trial NCT01787617?

This trial is currently completed. It is a NA study. The enrollment target is 113 participants. The study started on 2012-12. Estimated completion is 2018-03-31.

What conditions does trial NCT01787617 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Insulin Resistance.

What interventions are being tested in trial NCT01787617?

The interventions under investigation include: Control Group (BEHAVIORAL), Aerobic Plus Resistance Training Group (BEHAVIORAL).

Who is sponsoring clinical trial NCT01787617?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01787617 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.